Ian Setliff

Antibodies, Immunology, Protein Engineering, Comp Bio. @urichmond, @VanderbiltU and @Regeneron alum. Views mine.

[Cell Reports Methods @CellRepMethods]

TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells https://t.co/0CNOP2nhnO

[Ivelin Georgiev, Ph.D. @IG_lab]

High-throughput discovery of #epitope-specific #antibodies? There's a #LIBRAseq for that. Great collaborative effort led by @LaurenW_Science.

High-Throughput B Cell Epitope Determination by Next-Generation Sequencing https://t.co/mOF9nIepNV

[Ivelin Georgiev, Ph.D. @IG_lab]

#LIBRAseq with ligand blocking enables targeted discovery of functional (not just binding) #antibodies.

Double #ACE2-blockers for both #SARSCoV2 and #SARSCoV were also identified.

Easily generalizable for #mAb discovery aiming to block other types of antigen-ligand interactions

[Ian Setliff @IanSetliff]

Great place to do science!

[Ivelin Georgiev, Ph.D. @IG_lab]

We have a postdoctoral opening in antibody discovery, with a special emphasis on the development and application of innovative #bioinformatics technologies.

Come do cutting-edge research in #antibody and #vaccine science in #Nashville, one of the hottest destinations in the US!

[Ian Setliff @IanSetliff]

Congrats @IG_lab @kjkramer6 @AShiakolas and all

[Ivelin Georgiev, Ph.D. @IG_lab]

Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition https://t.co/S32vvFZmix

[Ivelin Georgiev, Ph.D. @IG_lab]

Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition https://t.co/S32vvFZmix

[Regeneron @Regeneron]

More #COVID19 News: Positive results from a Phase 3 trial in recently infected asymptomatic patients demonstrate the ability of our investigational antibody cocktail to reduce progression to symptomatic #COVID19. Learn more: https://t.co/rziZOWmcVi

[Ian Setliff @IanSetliff]

@PilewskiKelsey It’s the thought that counts!

[Regeneron @Regeneron]

Announcing our Phase 3 trial in advanced #CervicalCancer was stopped early after achieving its primary efficacy endpoint. Today’s milestone is a “first” for the cervical cancer community. Learn why: https://t.co/ePL40tmYfR CC: @Sanofi

[Regeneron @Regeneron]

Today, the FDA accepted for review our sBLA for a treatment for children aged 6 to 11 years with moderate-to-severe #asthma. Learn more: https://t.co/9udThffNN0 @sanofi

[Ian Setliff @IanSetliff]

We're looking for a computational immunologist. Come join us! https://t.co/OinQScKeJz

[Regeneron @Regeneron]

We announced new data on our investigational medicine for patients with #cat allergy and mild asthma at #AAAAI21. Learn more: https://t.co/vKZlP3MqWo

[Regeneron @Regeneron]

With @Sanofi, we are announcing the FDA approval of our #immunotherapy in first-line advanced #NonSmallCellLungCancer (#NSCLC) with ≥50% PD-L1 expression. Learn more: https://t.co/A5PzpTqoz0

[Ian Setliff @IanSetliff]

@WyattMcDonnell or farfarout_v2, farfarout_final, farfarout_final_v2...

[Regeneron @Regeneron]

Today the FDA approved a first-of-its-kind treatment for people with #HoFH, an ultra #rare inherited form of high cholesterol. Read the full announcement: https://t.co/C7ojzpAH8v

[Regeneron @Regeneron]

Announcing with @Sanofi, the FDA has granted full approval to our #immunotherapy for patients with locally advanced #BasalCell Carcinoma (#BCC) and accelerated approval for patients with metastatic #BCC. Learn more: https://t.co/Zu8cicfaad

[Ian Setliff @IanSetliff]

Great place to do science!

[Regeneron @Regeneron]

Pursue your passion for #science in a dynamic and innovative environment. Apply by December 1 to be a part of the Regeneron Postdoctoral Program.

[Regeneron @Regeneron]

The FDA has issued an Emergency Use Authorization for our investigational antibody cocktail to treat mild to moderate #COVID19 in certain high-risk patients 12 years and older. Learn more: https://t.co/yNfOFPyLI0

[Regeneron @Regeneron]

Announcing positive data from 524 additional non-hospitalized #COVID19 patients in ongoing P2/3 study of Regeneron’s investigational antibody cocktail: https://t.co/FOVKNlZRn0